NHLBI

Displaying 1 - 6 of 6

Vanderbilt study suggests way to prevent rare lung disease

Vanderbilt study suggests way to prevent rare lung disease

Related Categories: 
American Heart Association biomedical engineering David Merryman Department of Pediatrics Department of Pharmacology NIH NHLBI circulation research

Team’s findings show glutamine metabolism affects T cell signaling

Team’s findings show glutamine metabolism affects T cell signaling

Related Categories: 
Autoimmune disease cancer immunotherapy CAR T Therapy Cell Cell Metabolism center for immunobiology glutamine immunotherapy inflammation jeffrey rathmell NCI NHLBI NIH. Pathology microbiology and immunology t cell

Stretch, inflammation and hypertension

Monocytes are known to play an important role in hypertension, although the exact mechanism remains unclear. It is hypothesized that a potential source of monocyte activation originates from its interaction with the vascular endothelium.

Related Categories: 
Health Medicine Research American Heart Association Cardiovascular David Harrison Department of Medicine Division of Clinical Pharmacology hypertension immune response NHLBI NIH

Unleashing TIGER on small RNAs

Efforts to explore the landscape of small RNAs (sRNAs) — short RNA molecules that are poorly understood — often use high-throughput sequencing (sRNA-seq). These efforts are hampered by a lack of tools to identify, quantify and analyze all the different sRNAs in sRNA-seq datasets.

Related Categories: 
American Heart Association Basic Sciences Department of Medicine Journal of Extracellular Vesicles Kasey Vickers Molecular Physiology & Biophysics NCATS NCI NHLBI NIDDK NIGMS NIH RNA

Scavengers “protect” HDL

High-density lipoprotein (HDL) is widely thought to protect against the development of atherosclerosis, yet drugs that raise levels of HDL cholesterol (HDL-C) have failed to reduce the risk of heart disease.

Related Categories: 
AHA American Heart Association atherosclerosis Basic Sciences cholesterol Department of Pharmacology HDL Journal of Biological Chemistry NHLBI NIH Research Sean Davies

A “public” target for HIV

Individuals produce unique sets of antibodies in response to HIV infection. That diversity — and the ability of the human immunodeficiency virus to rapidly change its protein coat to avoid detection — has stymied efforts to develop an anti-HIV vaccine.

Related Categories: 
Health and Medicine Gates Foundation HIV HIV/AIDS Ivelin Georgiev NCATS NHLBI NIAID NIGMS NIH pathology microbiology and immunology Vaccine Vanderbilt Vaccine Center